The cumulative effects of intravenous antibiotic treatments on hearing in patients with cystic fibrosis
| Autor: | Angela C. Garinis, Priya Srikanth, Lisa L. Hunter, Douglas H. Keefe, Daniel B. Putterman, David M. Cohen, M. Patrick Feeney, Jeffrey A. Gold, Peter S. Steyger, Kelly Carroll, Campbell P. Cross |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
0301 basic medicine
Pulmonary and Respiratory Medicine Adult Male medicine.medical_specialty Adolescent Cystic Fibrosis Hearing loss 030106 microbiology Audiology Cystic fibrosis Article Time 03 medical and health sciences 0302 clinical medicine Sex Factors Vancomycin Internal medicine otorhinolaryngologic diseases medicine Tobramycin Humans Dosing 030223 otorhinolaryngology Hearing Loss Amikacin medicine.diagnostic_test business.industry Age Factors Bacterial Infections Middle Aged medicine.disease United States Anti-Bacterial Agents Patient Outcome Assessment Pediatrics Perinatology and Child Health Hearing test Audiometry Pure-Tone Sensorineural hearing loss Female medicine.symptom Audiometry business medicine.drug |
| Zdroj: | Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society. 16(3) |
| ISSN: | 1873-5010 |
| Popis: | Background Aminoglycosides (AGs) and glycopeptides are antibiotics essential for treating life-threatening respiratory infections in patients with cystic fibrosis (CF). The goal of this study was to examine the effects of cumulative intravenous (IV)-AG (amikacin and/or tobramycin) and/or glycopeptide (vancomycin) dosing on hearing status in patients with CF. Methods Hearing thresholds were measured from 0.25 to 16.0kHz, in 81 participants with CF. Participants were categorized into two groups: normal hearing in both ears (≤25dB HL for all frequency bands) or hearing loss (>25dB HL for any frequency band in either ear). Participants were also characterized into quartiles by their cumulative IV-AG (with or without vancomycin) exposure. Dosing was calculated using two strategies: (i) total number of lifetime doses, and (ii) total number of lifetime doses while accounting for the total doses per day. This was referred to as the "weighted" method. Results Participants in the hearing loss group were significantly older than those in the normal-hearing group. After adjusting for gender and age at the time of hearing test, participants in the two highest-quartile exposure groups were almost 5 X more likely to have permanent sensorineural hearing loss than those in the two lowest-quartile exposure groups. There was a small group of CF patients who had normal hearing despite high exposure to IV-antibiotics. Conclusions Cumulative IV-antibiotic dosing has a significant negative effect on hearing sensitivity in patients with CF, when controlling for age and gender effects. A trend for increasing odds of hearing loss was associated with increasing cumulative IV-antibiotic dosing. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect